A reverse-ELISA for the detection of TRIM28/KAP1 serum autoantibodies in colorectal cancer patients

Figures & data

Table I. Details of patient cohort.

	Colorectal Cancer	Non-cancer control
Total	58	55
No cancer		55
Stage I	7
Stage II	15
Stage III	21
Stage IV	15
Gender
Male	41	21
Female	17	34
Median age (years)	66	46.7
Age range (years)	29–90	22–73

Figure 1. Detection of antibodies to TRIM28 in colorectal cancer (‘CRC’; n = 58) and control (n = 55) patient serum as determined by reverse ELISA conditions. Seropositivity in colorectal cancer patients was determined by whether an individual's absorbance value was greater than control mean absorbance + 2SD (dashed line).